Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX - Get Free Report)'s share price fell 5.2% during tradin

Lexicon Pharmaceuticals (NASDAQ:LXRX) held its second-quarter earnings conference call on Thursday.

Lexicon Pharmaceuticals, Inc. upgraded to Buy as multiple near-term catalysts emerge across its pipe

He feels it's a clear buy at the current price. In his view, sotagliflozin has excellent potential t

Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX - Get Free Report) have received an average ra

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys

Analysts initiate coverage: Buy on IonQ ($60), Jack Henry ($193) and 10X Genomics ($110); Overweight

Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Lexicon Pharmaceuticals (NASDAQ:L

Lexicon Pharmaceuticals (NASDAQ: LXRX) said it has completed enrollment in its Phase III SONATA-HCM

Lexicon Pharmaceuticals NASDAQ: LXRX said it has completed enrollment in its Phase III SONATA-HCM st

U.S. stock futures rose, but Beta Bionics fell 7.1% after pricing a stock offering; several other st

Tempest shares surged 49.6% on a Senlang CD7 CAR-T option deal, while several small-cap stocks poste

Lexicon Pharmaceuticals, Inc. (LXRX) Presents at Citigroup's Biopharma Back to School Summit 2026 Tr

THE WOODLANDS, Texas, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX

Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart Failure Findings

LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the trea

Lexicon Pharmaceuticals (LXRX) is nearing multiple potential value-transforming events for sotaglifl

Lexicon Pharmaceuticals NASDAQ: LXRX reported a wider second-quarter loss as revenue declined sharpl

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call Transcript

Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.06 per share in line with the Za

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.07) per share which missed th

Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027  NDA resubmission ac

THE WOODLANDS, Texas, July 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX)

The study substantially exceeded its enrollment target of 500 patients across more than 130 sites in

Study substantially exceeded enrollment target of 500 patients Topline results anticipated in Q1 202

Lexicon advances sotagliflozin into new indications while its obesity and pain programs progress, se

One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale

Citigroup analyst Yigal Nochomovitz maintains Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy an

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly sales of $1.090 million which missed the an

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that results from its PROGRESS Phase 2b

U.S. stock futures up, Dow gains 150 points. Avis Budget Group (CAR) shares fall 9.6% in pre-market.

U.S. stock futures fell on Monday after three consecutive days of decline on Friday. Futures of benc